Vi多糖-破伤风类毒素结合疫苗(Typbar TCV®)在<2岁儿童初次接种后7年内的持续抗体应答
本研究对327名6-23月龄接种Typbar TCV®的儿童进行7年随访,其中193名在初种后2年加强。加强组和非加强组抗Vi IgG几何平均滴度在3、5、7年分别维持高于基线32/14/10倍和21/8/5倍。加强组持续血清转化率更高,建议在学龄前加强以延长保护。
要点
- 加强组7年时GMT仍为基线10倍,非加强组为5倍
- 7年时非加强组71%持续血清转化,加强组84%
- 建议初种后约5年(学龄前)加强一剂
核心结论
- Typbar TCV®初种后7年抗体应答持续存在,加强组高于非加强组。
- 为延长保护,建议在初种后约5年(学龄前)加强一剂。
研究设计与样本
- 对327名6-23月龄接种Typbar TCV®的儿童进行随访,其中193名在初种后720天加强。
- 在初种后3、5、7年用三种ELISA监测抗Vi IgG。
- 分析包括持续血清转化、GMT、几何平均倍数上升和 putative 保护水平(≥2 µgSzu/ml)。
主要发现
- 加强组(N=86)Vacczyme™ GMT在762天显著升高,3、5、7年分别为基线32、14、10倍。
- 非加强组(N=25)GMT分别为基线21、8、5倍。
- 非加强组持续血清转化率5年72%、7年44%;加强组分别为84%、71%。
- Szu和NIBSC ELISA显示非加强组7年92-100%持续血清转化,100%超过Szu保护阈值。
关键数值与推荐
- 持续血清转化定义:滴度保持≥基线4倍。
- putative保护水平:≥2 µgSzu/ml(Szu法,NIH IgG参考标准)。
临床怎么用
- 对<2岁接种Typbar TCV®的儿童,可在初种后约5年(学龄前)加强一剂以延长保护。
- 监测抗体持久性时可参考Vacczyme™、Szu和NIBSC ELISA结果。
局限性
- 加强组与非加强组持续血清转化率差异除第3年外无统计学显著性。
- 部分亚组样本量较小(如非加强ASC组N=25)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Serum IgG anti-Vi titers attained by 327 children 6-23 months of age immunized with Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®), of whom 193/327 received a booster dose 2 years post-primary vaccination, were previously reported. METHODS: Anti-Vi IgG in boosted and unboosted children 3, 5, and 7 years post-primary immunization were monitored using three different enzyme-linked immunosorbent assays (ELISAs): Vacczyme™ kit ELISA (all specimens); "Szu" ELISA (all specimens), and National Institute of Biological Standards NIBSC ELISA (subset). Endpoints analyzed included: persisting seroconversion (titer remaining ≥ 4-fold above baseline), geometric mean titer (GMT), geometric mean-fold rise post-vaccination, and percent exhibiting putative protective anti-Vi level (≥2 µgSzu/ml) using Szu method and National Institutes of Health IgG reference standard. In assessing the persistence of elevated anti-Vi titers stimulated by Typbar-TCV®, four subgroups were compared based on whether or not the initially enrolled children were boosted on day 720 and whether they provided serum on all key timepoints, or if they missed one or more timepoints: i) Among boosted participants, an "All Specimens Cohort" (ASC) comprised 86 children who provided sera on days 42, 720 (booster), 762 (42 days post-booster), 1095, 1825 and 2555, to define kinetics of the Vi antibody response in a fully compliant cohort of boosted children monitored over seven years; ii) Among non-boosted subjects, a compliant All Specimens Cohort of 25 children provided sera on days 0, 42, 720, 1095, 1825, and 2555; iii) Among boosted children, an "Any Available Specimen" (AAS) subgroup consisted of boosted children who provided sera on days 0, 42, and 720 days and also on one or more of days 762, 1095, 1825, or 2555 but not on all those time points; iv) Among the non-boosted subjects, there was also an Any Available Specimen subgroup of 47 children who provided sera on days 0 and 42, of whom 41 subsequently contributed sera on one or more of days 1095, 1825 and 2555. RESULTS: Vacczyme™ GMTs among boosted ASC children (N = 86) increased significantly on day 762, and remained 32-fold, 14-fold, and 10-fold over baseline at 3, 5 and 7 years; among unboosted ASC children (N = 25), GMTs remained 21-fold, 8-fold and 5-fold over baseline, respectively. Post-primary vaccination, 72% and 44% of unboosted ASC subjects (N = 25) exhibited persisting seroconversion by Vacczyme™ at 5 and 7 years, respectively; the corresponding numbers for ASC boosted subjects were 84% and 71%. Amongst the four sub-groups, boosted subjects showed higher prevalence of persisting seroconversion at most time points with the gap widening by 7th year, though not statistically significant (except 3rd year). Tested by Szu and also NIBSC ELISAs, 92-100% of unboosted ASC children showed persisting seroconversion at 7 years with 100% also exceeding the Szu protective threshold. CONCLUSION: To extend protection, administering a booster of Typbar TCV® to children ∼5 years after their primary dose, i.e., coinciding with school entry, may be advisable. Typbar TCV® is presently the only WHO pre-qualified Vi conjugate vaccine with reported efficacy, effectiveness, and long-term immunogenicity findings.
引用
- Vadrevu KM, Raju D, Rani S, et al. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination. Vaccine. 2021. PMID: 34625288. doi:10.1016/j.vaccine.2021.07.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。